{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T22:21:58Z","timestamp":1758925318488,"version":"3.37.3"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T00:00:00Z","timestamp":1610496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Department of Pathology"},{"name":"Stead Family Department of Pediatrics"},{"name":"University of Iowa Hospital and Clinics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We sought to investigate the clinical utility of flow cytometry (FC) and fluorescence in situ hybridization (FISH) in the workup of myeloma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively reviewed the reports of bone marrow biopsies received for myeloma evaluation between October 2015 and January 2019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1,708 biopsy specimens from 469 myeloma patients (mean age, 64.5 years [SD, 9.3]; female, 41.4%) were reviewed. Both FC and FISH had comparable detection rates at the time of initial diagnosis (97.6% vs 98.8%) and for follow-up cases (28.6% vs 28.2%). FC and FISH results were concordant in 98.8% of the initial diagnosis cases and 89.6% of the follow-up cases. The FISH-positive (FISH+)\/FC-negative (FC\u2212) discordance and FISH\u2212\/FC+ discordance occurred among 81 (5.0%) and 87 (5.4%) follow-up cases. In comparison with all concordant cases, FISH+\/FC\u2212 discordant cases were more likely to have received treatment with daratumumab (P &amp;lt; .05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Plasma cell\u2013enriched FISH and FC have comparable abnormal plasma cell detection rates, and approximately 10% of the follow-up cases have discordant FISH and FC results in which residual disease is detected by only one of these modalities. FISH testing should be considered for cases with negative FC, especially in patients who have received treatment with daratumumab or in cases in which there is concern about specimen adequacy.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ajcp\/aqaa224","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T19:11:35Z","timestamp":1601579495000},"page":"198-204","source":"Crossref","is-referenced-by-count":3,"title":["Utility of Flow Cytometry and Fluorescence In Situ Hybridization in Follow-up Monitoring of Plasma Cell Myeloma"],"prefix":"10.1093","volume":"156","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5872-0532","authenticated-orcid":false,"given":"Saurav","family":"Chopra","sequence":"first","affiliation":[{"name":"Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Dunham","sequence":"additional","affiliation":[{"name":"Stead Family Department of Pediatrics, University of Iowa Hospitals and Clinics, Iowa City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergei I","family":"Syrbu","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitin J","family":"Karandikar","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin W","family":"Darbro","sequence":"additional","affiliation":[{"name":"Stead Family Department of Pediatrics, University of Iowa Hospitals and Clinics, Iowa City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5748-9914","authenticated-orcid":false,"given":"Carol J","family":"Holman","sequence":"additional","affiliation":[{"name":"Department of Pathology"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,1,13]]},"reference":[{"key":"2021070713340536900_CIT0001","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"CA Cancer J Clin."},{"key":"2021070713340536900_CIT0002","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"2021070713340536900_CIT0003","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1158\/1078-0432.CCR-14-2841","article-title":"Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?","volume":"21","author":"Paiva","year":"2015","journal-title":"Clin Cancer Res."},{"key":"2021070713340536900_CIT0004","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood."},{"key":"2021070713340536900_CIT0005","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood."},{"key":"2021070713340536900_CIT0006","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/ijlh.12757","article-title":"Minimal residual disease in multiple myeloma: benefits of flow cytometry","volume":"40","author":"Galtseva","year":"2018","journal-title":"Int J Lab Hematol."},{"key":"2021070713340536900_CIT0007","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1309\/AJCPF7NFLW8UAJEP","article-title":"Detection of genomic abnormalities in multiple myeloma: the application of FISH analysis in combination with various plasma cell enrichment techniques","volume":"136","author":"Hartmann","year":"2011","journal-title":"Am J Clin Pathol."},{"key":"2021070713340536900_CIT0008","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12308-015-0264-1","article-title":"Clinical utility of morphology, immunohistochemistry, flow cytometry, and FISH analysis in monitoring of plasma cell neoplasms in the bone marrow","volume":"9","author":"Ajise","year":"2016","journal-title":"J Hematopathol."},{"key":"2021070713340536900_CIT0009","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1309\/B2P9XEH44CY9LPUK","article-title":"Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow","volume":"125","author":"Zhao","year":"2006","journal-title":"Am J Clin Pathol."},{"key":"2021070713340536900_CIT0010","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.humpath.2007.04.010","article-title":"Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry","volume":"38","author":"Al-Quran","year":"2007","journal-title":"Hum Pathol."},{"key":"2021070713340536900_CIT0011","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/cyto.b.20517","article-title":"Multiparameter immunophenotyping by flow cytometry in multiple myeloma: the diagnostic utility of defining ranges of normal antigenic expression in comparison to histology","volume":"78","author":"Cannizzo","year":"2010","journal-title":"Cytometry B Clin Cytom."},{"key":"2021070713340536900_CIT0012","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1751-553X.2011.01323.x","article-title":"Correlation of assessment of plasma cells by flow cytometry and detection of cytogenomic abnormalities by fluorescence in situ hybridization in plasma cell neoplasms","volume":"33","author":"Lu","year":"2011","journal-title":"Int J Lab Hematol."},{"key":"2021070713340536900_CIT0013","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/leu.2013.217","article-title":"Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma: a comparative analysis with flow cytometry","volume":"28","author":"Puig","year":"2014","journal-title":"Leukemia."},{"key":"2021070713340536900_CIT0014","first-page":"1365","article-title":"Minimal residual disease monitoring in multiple myeloma: a comparison between allelic-specific oligonucleotide real-time quantitative polymerase chain reaction and flow cytometry","volume":"90","author":"Sarasquete","year":"2005","journal-title":"Haematologica."},{"key":"2021070713340536900_CIT0015","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1751-553X.2012.01433.x","article-title":"Application of an immune-magnetic cell sorting method for CD138-positive plasma cells in FISH analysis of multiple myeloma","volume":"34","author":"Shin","year":"2012","journal-title":"Int J Lab Hematol."},{"key":"2021070713340536900_CIT0016","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.cancergencyto.2008.11.007","article-title":"Interphase FISH in plasma cell dyscrasia: increase in abnormality detection with plasma cell enrichment","volume":"189","author":"Pozdnyakova","year":"2009","journal-title":"Cancer Genet Cytogenet."},{"key":"2021070713340536900_CIT0017","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2010-10-300970","article-title":"Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2","volume":"117","author":"Munshi","year":"2011","journal-title":"Blood."},{"key":"2021070713340536900_CIT0018","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41375-019-0590-x","article-title":"Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma","volume":"34","author":"An","year":"2020","journal-title":"Leukemia."},{"key":"2021070713340536900_CIT0019","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1177\/2040620716682490","article-title":"New monoclonal antibodies on the horizon in multiple myeloma","volume":"8","author":"O\u2019Donnell","year":"2017","journal-title":"Ther Adv Hematol."},{"key":"2021070713340536900_CIT0020","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia."},{"key":"2021070713340536900_CIT0021","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cyto.b.21279","article-title":"Multiple myeloma: new surface antigens for the characterization of plasma cells in the era of novel agents","volume":"90","author":"Muccio","year":"2016","journal-title":"Cytometry B Clin Cytom."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/156\/2\/198\/38877962\/aqaa224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ajcp\/article-pdf\/156\/2\/198\/38877962\/aqaa224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T03:59:00Z","timestamp":1698206340000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/156\/2\/198\/6092407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,13]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1,13]]},"published-print":{"date-parts":[[2021,7,6]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqaa224","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"type":"print","value":"0002-9173"},{"type":"electronic","value":"1943-7722"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,1,13]]}}}